Answers are grounded in this paper and cite their sources.
In men with CAD and elevated LDL-C, Lp(a) levels were dominant correlates of baseline disease severity, its progression, and event rate over 2.5 years. However, with substantial LDL-C reductions, persistent elevations of Lp(a) were no longer atherogenic or clinically threatening. This provides a possible direction for treatment in such patients with elevated Lp(a) and LDL-C.
No takes yet. Share an insight, caveat, or question.
Vincent Maher (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: